Hypoxia-Responsive Nano-Photosensitizer Anchored by PEGylated BODIPY: A Single-Laser-Driven Platform for Photo-Enhanced Synergistic Chemo/Photodynamic/Photothermal Cancer Therapy

IF 4.5 2区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL
De-Chao Yang, Huamei Zhuang, Jiayi Zheng, Liyang Du*, Jianmin Chen* and Jian-Yong Liu*, 
{"title":"Hypoxia-Responsive Nano-Photosensitizer Anchored by PEGylated BODIPY: A Single-Laser-Driven Platform for Photo-Enhanced Synergistic Chemo/Photodynamic/Photothermal Cancer Therapy","authors":"De-Chao Yang,&nbsp;Huamei Zhuang,&nbsp;Jiayi Zheng,&nbsp;Liyang Du*,&nbsp;Jianmin Chen* and Jian-Yong Liu*,&nbsp;","doi":"10.1021/acs.molpharmaceut.5c00646","DOIUrl":null,"url":null,"abstract":"<p >The integration of chemotherapeutic drugs and photosensitizers into nanocarriers holds great potential for combining chemotherapy and phototherapy while reducing systemic toxicity. However, therapeutic efficacy is hindered by the hypoxic tumor microenvironment and the insufficient drug release. This study designs a multifunctional nano-photosensitizer BAP by conjugating hydrophobic boron dipyrromethene (BODIPY) with hydrophilic poly(ethylene glycol) via hypoxia-responsive azobenzene linkers. In aqueous media, BAP demonstrates self-assembly into stable nanoparticles (termed BAP NPs) that exhibit dual phototherapeutic functionalities. BAP NPs can be activated by single wavelength laser irradiation to initiate both photodynamic therapy (PDT) and photothermal therapy (PTT). The engineered BAP NPs further integrate dual-mode imaging capabilities, enabling fluorescence and photothermal imaging for nanocarrier visualization. To enhance antitumor efficacy, the chemotherapy doxorubicin (DOX) was further loaded into BAP NPs, forming nanomedicine BAP-DOX NPs. As expected, the azobenzene linkers of BAP are sensitive to the overexpressed azoreductase in hypoxic cancer cells, facilitating BAP disassembly and DOX release. Upon laser irradiation, the BAP component in BAP-DOX NPs eradicates superficial oxygen-rich tumor cells through PDT and PTT. PDT-caused oxygen consumption triggers acute hypoxia, enhancing DOX release in hypoxic tumor cells. Both in vitro and in vivo studies have demonstrated that BAP-DOX NPs exhibit remarkable antitumor activity through synergistic light-driven PDT/PTT and hypoxia-responsive chemotherapy. This research establishes an innovative therapeutic strategy to overcome hypoxia-induced therapeutic resistance through a simple photosensitizer-based nanocarrier that enables photo-enhanced drug release and synergistic chemo/photodynamic/photothermal tumor ablation.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":"22 9","pages":"5603–5615"},"PeriodicalIF":4.5000,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Pharmaceutics","FirstCategoryId":"3","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.5c00646","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

The integration of chemotherapeutic drugs and photosensitizers into nanocarriers holds great potential for combining chemotherapy and phototherapy while reducing systemic toxicity. However, therapeutic efficacy is hindered by the hypoxic tumor microenvironment and the insufficient drug release. This study designs a multifunctional nano-photosensitizer BAP by conjugating hydrophobic boron dipyrromethene (BODIPY) with hydrophilic poly(ethylene glycol) via hypoxia-responsive azobenzene linkers. In aqueous media, BAP demonstrates self-assembly into stable nanoparticles (termed BAP NPs) that exhibit dual phototherapeutic functionalities. BAP NPs can be activated by single wavelength laser irradiation to initiate both photodynamic therapy (PDT) and photothermal therapy (PTT). The engineered BAP NPs further integrate dual-mode imaging capabilities, enabling fluorescence and photothermal imaging for nanocarrier visualization. To enhance antitumor efficacy, the chemotherapy doxorubicin (DOX) was further loaded into BAP NPs, forming nanomedicine BAP-DOX NPs. As expected, the azobenzene linkers of BAP are sensitive to the overexpressed azoreductase in hypoxic cancer cells, facilitating BAP disassembly and DOX release. Upon laser irradiation, the BAP component in BAP-DOX NPs eradicates superficial oxygen-rich tumor cells through PDT and PTT. PDT-caused oxygen consumption triggers acute hypoxia, enhancing DOX release in hypoxic tumor cells. Both in vitro and in vivo studies have demonstrated that BAP-DOX NPs exhibit remarkable antitumor activity through synergistic light-driven PDT/PTT and hypoxia-responsive chemotherapy. This research establishes an innovative therapeutic strategy to overcome hypoxia-induced therapeutic resistance through a simple photosensitizer-based nanocarrier that enables photo-enhanced drug release and synergistic chemo/photodynamic/photothermal tumor ablation.

Abstract Image

由聚乙二醇化BODIPY锚定的低氧反应纳米光敏剂:光增强协同化疗/光动力/光热癌症治疗的单激光驱动平台。
将化疗药物和光敏剂整合到纳米载体中,在降低全身毒性的同时,具有将化疗和光疗结合起来的巨大潜力。但由于肿瘤微环境缺氧,药物释放不足,影响了治疗效果。本研究通过低氧响应偶氮苯连接剂将疏水二吡咯烯硼(BODIPY)与亲水性聚乙二醇偶联,设计了一种多功能纳米光敏剂BAP。在水介质中,BAP表现出自组装成稳定的纳米颗粒(称为BAP NPs),具有双重光疗功能。BAP NPs可以通过单波长激光照射激活,启动光动力治疗(PDT)和光热治疗(PTT)。设计的BAP NPs进一步集成了双模成像能力,实现了纳米载体可视化的荧光和光热成像。为了增强抗肿瘤效果,化疗药物阿霉素(DOX)进一步加载到BAP NPs中,形成纳米药物BAP-DOX NPs。正如预期的那样,BAP的偶氮苯连接物对缺氧癌细胞中过表达的偶氮还原酶敏感,促进BAP的分解和DOX的释放。激光照射后,BAP- dox NPs中的BAP成分通过PDT和PTT清除浅表富氧肿瘤细胞。pdt引起的耗氧触发急性缺氧,促进缺氧肿瘤细胞中DOX的释放。体外和体内研究表明,BAP-DOX NPs通过协同光驱动PDT/PTT和缺氧反应性化疗表现出显著的抗肿瘤活性。本研究建立了一种创新的治疗策略,通过一种简单的基于光敏剂的纳米载体来克服缺氧诱导的治疗耐药性,这种纳米载体可以实现光增强药物释放和协同化疗/光动力/光热肿瘤消融。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Molecular Pharmaceutics
Molecular Pharmaceutics 医学-药学
CiteScore
8.00
自引率
6.10%
发文量
391
审稿时长
2 months
期刊介绍: Molecular Pharmaceutics publishes the results of original research that contributes significantly to the molecular mechanistic understanding of drug delivery and drug delivery systems. The journal encourages contributions describing research at the interface of drug discovery and drug development. Scientific areas within the scope of the journal include physical and pharmaceutical chemistry, biochemistry and biophysics, molecular and cellular biology, and polymer and materials science as they relate to drug and drug delivery system efficacy. Mechanistic Drug Delivery and Drug Targeting research on modulating activity and efficacy of a drug or drug product is within the scope of Molecular Pharmaceutics. Theoretical and experimental peer-reviewed research articles, communications, reviews, and perspectives are welcomed.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信